Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.66 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.63 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.63 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.63 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MPI | P34949 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8541773 | 0.87 | SMPD3 (0.58) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL12714764 | 0.85 | SMPD3 (0.60) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL27963202 | 0.85 | SMPD3 (0.56) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL3368911 | 0.85 | SMPD3 (0.56) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL5803059 | 0.85 | SMPD3 (0.69) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL27803371 | 0.85 | SMPD3 (0.65) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL6002654 | 0.85 | SMPD3 (0.56) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL9850693 | 0.84 | SMPD3 (0.51) | SMPD3TLR9TLR8TLR7KDM4E | |
| SCHEMBL5756185 | 0.83 | TSHR (0.56) | SMPD3TLR9TLR8TLR7NISCH | |
| SCHEMBL28911235 | 0.83 | TLR9 (0.55) | SMPD3TLR9TLR8TLR7NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105164125-B | 2-phenyl or 2-heteroaryl imidazo [1,2-a ] pyridine derivatives | 豪夫迈·罗氏有限公司 | 2017-10-13 | — | — | CN | claimed |
| CN-105164125-A | 2-phenyl or 2-heteroaryl imidazo [1, 2-a ] pyridine derivatives | HOFFMANN LA ROCHE | 2015-12-16 | — | — | CN | claimed |
| CN-1529597-A | Imidazo (1,2-A)_pyridine derivatives as mGLUR5 antagonists | - | 2004-09-15 | — | — | CN | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10022356-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-17 | — | — | US | disclosed |
| CN-105164125-B | 2-phenyl or 2-heteroaryl imidazo [1,2-a ] pyridine derivatives | 豪夫迈·罗氏有限公司 | 2017-10-13 | — | — | CN | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| CN-102388055-A | Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO | 2012-03-21 | — | — | CN | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| CN-1529597-A | Imidazo (1,2-A)_pyridine derivatives as mGLUR5 antagonists | - | 2004-09-15 | — | — | CN | disclosed |
| EP-0857171-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997015555-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
| US-4956470-A | BACTERICIDES, FUNGICIDES, ANTHELMINTICS, ANTIPROTOZOA AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1990-09-11 | — | — | US | disclosed |
| US-4814332-A | PARASITICIDES | HOFFMAN-LA ROCHE INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0253084-A2 | 1,3-Disubstituted imidazolium salts | F. HOFFMANN-LA ROCHE AG (CH) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | SMPD3 221/4885TLR9 3706/4885TLR8 4105/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885TLR9 3706/4885TLR8 4105/4885 |
| US-10022356-B2 | Compounds for treatment of cancer | BRAF, NRAS, RAF1 | SMPD3 2105/4885TLR9 4324/4885TLR8 4563/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | SMPD3 221/4885TLR9 3706/4885TLR8 4105/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885TLR9 3706/4885TLR8 4105/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885TLR9 3706/4885TLR8 4105/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885TLR9 3706/4885TLR8 4105/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | SMPD3 221/4885TLR9 3706/4885TLR8 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.